We are live on ! Find out more
HEPA

Hepion Pharmaceuticals

Delisted

HEPA was delisted on the 12th of May, 2025.

3 hedge funds and large institutions have $6.79M invested in Hepion Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more capital invested

Capital invested by funds: $4.44M → $6.79M (+$2.35M)

0% more funds holding

Funds holding: 33 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

Holders
3
Holders Change
Holders Change %
0%
% of All Funds
0.08%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
1
Increased
1
Reduced
Closed
1
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
TCIM
1
TIAA CREF Investment Management
New York
$3.98M +$559K +1 +100%
TA
2
Teachers Advisors
New York
$1.1M +$559K +1 New
Vanguard Group
3
Vanguard Group
Pennsylvania
$952K
Morgan Stanley
4
Morgan Stanley
New York
$249K
PFS
5
Prospera Financial Services
Texas
$186K
Geode Capital Management
6
Geode Capital Management
Massachusetts
$120K
Bank of Montreal
7
Bank of Montreal
Ontario, Canada
$31K
Bank of New York Mellon
8
Bank of New York Mellon
New York
$30K
Barclays
9
Barclays
United Kingdom
$27K
Cambridge Investment Research Advisors
10
Cambridge Investment Research Advisors
Iowa
$22K
Northern Trust
11
Northern Trust
Illinois
$18K
Nomura Holdings
12
Nomura Holdings
Japan
$17K
LWM
13
LBA Wealth Management
Florida
$15K
BIT
14
BlackRock Institutional Trust
California
$11K
EWA
15
Exencial Wealth Advisors
Oklahoma
$10K
BA
16
BlackRock Advisors
Delaware
$6K
BFA
17
BlackRock Fund Advisors
California
$5K
UBS Group
18
UBS Group
Switzerland
$5K
Wells Fargo
19
Wells Fargo
California
$3K
Royal Bank of Canada
20
Royal Bank of Canada
Ontario, Canada
$1K
SBL
21
Sargent Bickham Lagudis
Colorado
$1K
S
22
SignatureFD
Georgia
$1K
VIA
23
Vantage Investment Advisors
Pennsylvania
$1K
AFM
24
Anson Funds Management
Texas
-$1.37M -2 Closed
BIM
25
BlackRock Investment Management
Delaware
-$6K

HEPA Hedge Fund Activity: Q2 2016 in Review

3 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q2 2016, worth a combined $6.79M — up 53% from $4.44M a quarter earlier.

Fund positioning in HEPA was balanced in Q2 2016: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was Teachers Advisors, opening a new position worth an estimated $559K. The largest seller was Anson Funds Management, exiting entirely with an estimated $1.37M sold.

  • 3 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q2 2016, unchanged from Q1 2016.
  • Funds reported $6.79M of Hepion Pharmaceuticals stock for Q2 2016, up 53% quarter-over-quarter.
  • 1 fund opened new Hepion Pharmaceuticals positions in Q2 2016 and 1 closed out, a net change of 0 holders.
  • The largest Hepion Pharmaceuticals buyer in Q2 2016 was Teachers Advisors, an estimated $559K added.
  • The largest Hepion Pharmaceuticals seller in Q2 2016 was Anson Funds Management, an estimated $1.37M sold.

Based on aggregated 13F filings for Q2 2016.